CY1113299T1 - Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο - Google Patents

Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο

Info

Publication number
CY1113299T1
CY1113299T1 CY20121100562T CY121100562T CY1113299T1 CY 1113299 T1 CY1113299 T1 CY 1113299T1 CY 20121100562 T CY20121100562 T CY 20121100562T CY 121100562 T CY121100562 T CY 121100562T CY 1113299 T1 CY1113299 T1 CY 1113299T1
Authority
CY
Cyprus
Prior art keywords
blood
compound
transfer
protein polypeptide
relates
Prior art date
Application number
CY20121100562T
Other languages
English (en)
Inventor
RICHARD BéLIVEAU
Michel Demeule
Christian Ché
Anthony Regina
Original Assignee
Angiochem Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36916132&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113299(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angiochem Inc. filed Critical Angiochem Inc.
Publication of CY1113299T1 publication Critical patent/CY1113299T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με βελτιώσεις στον τομέα της χορήγησης φαρμάκων. Ειδικότερα, η εφεύρεση σχετίζεται με πολυπεπτίδια που προέρχονται από απροτινίνη και από ανάλογα απροτινίνης καθώς και συζεύγματα και φαρμακοτεχνικές συνθέσεις που περιέχουν αυτά τα πολυπεπτίδια ή συζεύγματα. Η παρούσα εφεύρεση σχετίζεται επίσης με την χρήση αυτών των πολυπεπτιδίων στην μεταφορά μιας ένωσης ή φαρμάκου μέσα στον αιματοεγκεφαλικό φραγμό ενός θηλαστικού και στην θεραπεία και διάγνωση νευρολογικών νόσων.
CY20121100562T 2005-02-18 2012-06-26 Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο CY1113299T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65392805P 2005-02-18 2005-02-18
EP05770546.9A EP1859041B2 (en) 2005-02-18 2005-07-21 Aprotinin polypeptides for transporting a compound across the blood-brain barrier

Publications (1)

Publication Number Publication Date
CY1113299T1 true CY1113299T1 (el) 2016-04-13

Family

ID=36916132

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100562T CY1113299T1 (el) 2005-02-18 2012-06-26 Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο

Country Status (19)

Country Link
US (4) US7902156B2 (el)
EP (2) EP2360258B1 (el)
JP (3) JP5175108B2 (el)
CN (2) CN101160403B (el)
AT (1) ATE551422T1 (el)
AU (1) AU2005327497B2 (el)
BR (1) BRPI0520032A2 (el)
CA (1) CA2597958C (el)
CY (1) CY1113299T1 (el)
DK (2) DK2360258T3 (el)
ES (2) ES2527634T3 (el)
HK (1) HK1116363A1 (el)
MX (1) MX2007010113A (el)
PL (2) PL1859041T5 (el)
PT (2) PT1859041E (el)
RU (2) RU2408605C2 (el)
SI (2) SI1859041T2 (el)
WO (1) WO2006086870A1 (el)
ZA (1) ZA200706917B (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1583562E (pt) * 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, compostos relacionados, e suas utilizações
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
CA2597958C (en) 2005-02-18 2019-01-15 Angiochem Inc. Molecules for transporting a compound across the blood-brain barrier
DK2433653T3 (da) * 2005-07-15 2019-08-19 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
CA2666841A1 (en) 2006-10-19 2008-04-24 Angiochem, Inc. Compounds for stimulating p-glycoprotein function and uses thereof
CA2688344C (en) * 2007-05-29 2019-09-03 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
DK2164866T3 (da) * 2007-05-29 2014-07-28 Angiochem Inc Aprotininlignende polypeptider til fremføring af midler, der er konjugeret dertil, til væv
MX2010006925A (es) * 2007-12-20 2011-05-02 Angiochem Inc Conjugados de polipeptido-acido nucleico y sus usos.
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
EP2279008B1 (en) * 2008-04-18 2019-03-06 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
JP2012505637A (ja) * 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
AU2009304505A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
WO2010063123A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
CN102307904A (zh) * 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
WO2010063124A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20100284921A1 (en) * 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
US20120196803A1 (en) * 2009-06-11 2012-08-02 Angiochem Inc. Fusion proteins for delivery of gdnf and bdnf to the central nervous system
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
US20120277158A1 (en) * 2009-10-06 2012-11-01 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
CN102812045B (zh) 2009-11-13 2018-04-13 第一三共欧洲有限公司 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法
EP2588490B1 (en) 2010-07-02 2017-02-22 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US20130280281A1 (en) * 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
CN102614524A (zh) * 2011-02-01 2012-08-01 复旦大学 低密度脂蛋白受体相关蛋白配体多肽修饰的脑肿瘤靶向基因递释复合物
WO2013056096A1 (en) * 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
US9687561B2 (en) 2012-08-14 2017-06-27 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
JP6108265B2 (ja) * 2012-11-19 2017-04-05 国立大学法人 千葉大学 脳送達用キャリアおよびその用途
EP3038657A2 (en) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
SG11201606824VA (en) * 2014-02-19 2016-09-29 Hoffmann La Roche Blood brain barrier shuttle
RU2703416C2 (ru) * 2014-03-28 2019-10-16 Эпосенс Лтд. Соединения для транс-мембранной доставки молекул
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
US9993563B2 (en) * 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
EP3200830B1 (en) 2014-10-03 2020-09-09 University of Massachusetts High efficiency library-identified aav vectors
WO2016061801A1 (zh) * 2014-10-24 2016-04-28 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
ES2874006T3 (es) * 2014-11-06 2021-11-04 Ose Immunotherapeutics Terapia inmune terapéutica específica con múltiples péptidos T para el tratamiento de la metástasis cerebral
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
JP6612063B2 (ja) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 悪性神経膠腫分子標的ペプチド
ES2826827T3 (es) * 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
PL417159A1 (pl) 2016-05-11 2017-11-20 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
US10702589B2 (en) 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
CA3049640A1 (en) 2017-01-09 2018-07-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
CN109666973B (zh) * 2018-11-21 2022-11-04 北京大学 一种穿过血脑屏障的肽库及其筛选方法
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
WO2022156531A1 (zh) * 2021-01-19 2022-07-28 中国人民解放军军事科学院军事医学研究院 一种能够透过生物屏障的动力蛋白结合肽及其应用
CN112851789B (zh) * 2021-02-04 2022-10-18 大理大学 一种脑靶向hiv进入抑制剂多肽及其应用
IL305326A (en) * 2021-02-22 2023-10-01 Univ Yale Targeted bifunctional degraders and methods for their use

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
ZA871844B (en) 1986-03-13 1988-05-25 Biotechnology Pty Ltd Method of assay of inhibin
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) * 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
WO1994007528A1 (en) 1992-09-25 1994-04-14 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia-tissue factor complex
WO1994019692A1 (en) 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
WO1996031531A2 (en) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
JPH11504938A (ja) * 1995-05-08 1999-05-11 サイオス インク． クニッツ型プロテアーゼ阻害因子
AU5908296A (en) 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
WO1997033996A2 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
JP2000509394A (ja) 1996-05-01 2000-07-25 アンティバイラルズ インコーポレイテッド 細胞膜を横切って物質を輸送するためのポリペプチド結合体
DE19629982A1 (de) * 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0975792B1 (en) 1997-03-04 2007-10-10 Savient Pharmaceuticals, Inc. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
MXPA01008699A (es) 1999-02-24 2002-06-21 Uab Research Foundation Derivados de taxano para terapia de cancer dirigida. .
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
CA2355334A1 (en) 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
AU2002254400B2 (en) 2001-03-23 2007-08-09 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
EP2147679B1 (en) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions for blood-brain barrier transport
CN1195845C (zh) * 2001-10-08 2005-04-06 中国医学科学院阜外心血管病医院 人源抑肽酶基因、该基因编码的蛋白质及其应用
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
CA2474283A1 (en) 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University In Jerusale M Amino acid sequences capable of facilitating penetration across a biological barrier
US20050215478A1 (en) * 2002-02-07 2005-09-29 Ben-Sasson Shmuel A Amino acid sequences capable of facilitating penetration across a biological barrier
US20040077540A1 (en) 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
PT1583562E (pt) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, compostos relacionados, e suas utilizações
WO2004108071A2 (en) 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP5624256B2 (ja) 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
WO2005014625A1 (ja) 2003-08-08 2005-02-17 Tissue Targeting Japan Inc. 脳移行活性を有するポリペプチド、およびその利用
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
DE602005015994D1 (de) 2004-09-29 2009-09-24 Childrens Memorial Hospital siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
CA2597958C (en) * 2005-02-18 2019-01-15 Angiochem Inc. Molecules for transporting a compound across the blood-brain barrier
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP1888121A2 (en) 2005-05-12 2008-02-20 Tapestry Pharmaceuticals, Inc. Anticancer targeted conjugates comprising a succinyl or glutaryl linker
DK2433653T3 (da) 2005-07-15 2019-08-19 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
JP2009507852A (ja) 2005-09-08 2009-02-26 エムディーアールエヌエー，インコーポレイテッド リボ核酸の細胞への送達用医薬組成物
KR20080086440A (ko) 2005-11-01 2008-09-25 알닐람 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 ＲＮＡｉ 억제
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
JP5102833B2 (ja) 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
CA2666841A1 (en) 2006-10-19 2008-04-24 Angiochem, Inc. Compounds for stimulating p-glycoprotein function and uses thereof
CA2688344C (en) 2007-05-29 2019-09-03 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8802631B2 (en) 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (en) 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
MX2010006925A (es) 2007-12-20 2011-05-02 Angiochem Inc Conjugados de polipeptido-acido nucleico y sus usos.
EP2279008B1 (en) 2008-04-18 2019-03-06 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
AU2009304505A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
WO2010063124A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
WO2010063123A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途

Also Published As

Publication number Publication date
RU2408605C2 (ru) 2011-01-10
CN104311653A (zh) 2015-01-28
US20080299039A1 (en) 2008-12-04
EP2360258A3 (en) 2011-12-14
US7902156B2 (en) 2011-03-08
JP5175108B2 (ja) 2013-04-03
SI1859041T1 (sl) 2012-07-31
SI2360258T1 (sl) 2015-02-27
ES2383901T5 (es) 2015-02-25
EP2360258A2 (en) 2011-08-24
PT2360258E (pt) 2015-01-13
US7557182B2 (en) 2009-07-07
DK1859041T3 (da) 2012-07-02
AU2005327497A1 (en) 2006-08-24
US8828949B2 (en) 2014-09-09
RU2611193C2 (ru) 2017-02-21
MX2007010113A (es) 2007-12-07
PL2360258T3 (pl) 2015-03-31
CN101160403A (zh) 2008-04-09
EP1859041B1 (en) 2012-03-28
AU2005327497B2 (en) 2012-04-12
JP2008529539A (ja) 2008-08-07
EP1859041A1 (en) 2007-11-28
PL1859041T5 (pl) 2015-05-29
ES2527634T3 (es) 2015-01-27
HK1116363A1 (en) 2008-12-19
US20060189515A1 (en) 2006-08-24
PL1859041T3 (pl) 2012-10-31
ZA200706917B (en) 2008-10-29
EP1859041A4 (en) 2008-10-08
SI1859041T2 (sl) 2015-04-30
ATE551422T1 (de) 2012-04-15
EP1859041B2 (en) 2014-11-19
WO2006086870A1 (en) 2006-08-24
DK1859041T4 (en) 2015-02-09
EP2360258B1 (en) 2014-10-08
DK2360258T3 (en) 2015-01-12
PT1859041E (pt) 2012-06-19
US20150174266A1 (en) 2015-06-25
CA2597958C (en) 2019-01-15
ES2383901T3 (es) 2012-06-27
CN104311653B (zh) 2017-12-05
CA2597958A1 (en) 2006-08-24
CN101160403B (zh) 2014-08-13
RU2010137915A (ru) 2012-03-20
US20110171128A1 (en) 2011-07-14
JP2014088386A (ja) 2014-05-15
BRPI0520032A2 (pt) 2009-04-14
RU2007134566A (ru) 2009-03-27
JP5462193B2 (ja) 2014-04-02
JP2011144174A (ja) 2011-07-28

Similar Documents

Publication Publication Date Title
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
CY1116762T1 (el) Πολυπεπτιδια, μεταβλητες περιοχες αντισωματος και ανταγωνιστες
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
WO2009075859A3 (en) Formulation of insulinotropic peptide conjugates
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
HK1089190A1 (en) Rasgap derived peptide for selectively killing cancer cells
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
HRP20161677T1 (hr) Pegilirani fab protiv amiloida beta
CO6331292A2 (es) Compuestos de insulina lispro pegilada
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
DE502004010644D1 (de) Geschmacksstoffhaltige arzneimittelformulierungen mit verbesserten pharmazeutischen eigenschaften
MX2011012677A (es) Conjugados de albumina-peptido amiloide y usos de los mismos.
WO2006135930A3 (en) Transmucosal delivery of peptide derivatives
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
CY1116049T1 (el) Πολυπεπτιδια απροτινινης για την μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
WO2008014232A3 (en) Pharmaceutical formulations for the treatment of alzheimer's disease
FR2925338B1 (fr) Peptide antimicrobien, medicament et composition pharmaceutique le contenant.
RU2005106768A (ru) Способ лечения хронических гонартринов у больных остеоартрозом
TH138518A (th) การให้ในปริมาณที่กำหนดของ her แอนติบอดี้